Resp &BioBased Risk FactorGuided Therapy Tx Pts w/NonHR N.blstma

Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: ANBL1232

    Protocol Abbrev: ANBL1232

    Principal Investigator: Vincent F. Giusti, MD

    Sub Investigators: AguilarBonilla, Ana MD; Eslin, Don MD; Martin, Rebecca, ARNP; Pope, Michele ARNP; Smith, Amy MD; Story, Allison ARNP; Sullivan Darden, Kelly ARNP; Sutphin, Robert MD; Wieber, Laura ARNP; Levy, Alejandro MD

    Phase: Drug: Phase III

    Age Group: Pediatric

    Secondary Protocol No: ANBL1232

    Treatment: Other: Clinical Observation Other: Laboratory Biomarker Analysis Drug: Chemotherapy (multiple)

    Applicable Disease Sites: Neuroblastoma, Medulloblastoma

    Therapies Involved: Chemotherapy ID: NCT02176967

  • Objective

    This trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients.

  • Key Eligibility

    Ages Eligible for Study: infants Genders eligible for Study: Both Accepts Healthy Volunteers: No